The patent entitiled ‘Sulfated Oligosaccharide Derivatives’ protects Progen’s PG500 series of small molecule compounds and their use in a variety of therapeutic areas predominantly related to oncology.
Progen Pharma Research and Development director Ian Bytheway said protection of the intellectual property by this patent strengthens and extends their drug development portfolio for the PG500 series technology.
Progen Pharma CEO Sue MacLeman said it is pleasing to announce the granting of this patent in such a commercially important region and it represents an important milestone in the development and commercialisation of PG500 series technology, from which their lead compound PG545 has already commenced human clinical trials.